Transfusion-dependent thalassaemia: A new era

Medical Journal of Australia

Volumn 188, Issue 2, 2008, Pages 68-69

  Berdoukas, Vasili ^a   Modell, Bernadette ^b  

^a Lefkos Stavros Hospital   (Greece)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; HEMOGLOBIN; IRON CHELATING AGENT; BENZOIC ACID DERIVATIVE; FERRITIN; PYRIDONE DERIVATIVE; SIDEROPHORE; TRIAZOLE DERIVATIVE;

ANEMIA; BLOOD TRANSFUSION; CARDIOMYOPATHY; CHELATION THERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDITORIAL; EVENING DOSAGE; HEART DEATH; HUMAN; INCIDENCE; IRON OVERLOAD; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; PRESCRIPTION; QUALITY OF LIFE; SIDE EFFECT; SURVIVAL; SYMPTOM; THALASSEMIA MAJOR; ERYTHROCYTE TRANSFUSION; HEART MUSCLE; METABOLISM; MORTALITY; NOTE; PATHOLOGY; STATISTICS; THALASSEMIA;

BENZOIC ACIDS; CARDIOMYOPATHIES; DEFEROXAMINE; ERYTHROCYTE TRANSFUSION; FERRITINS; HUMANS; IRON CHELATING AGENTS; MAGNETIC RESONANCE IMAGING; MYOCARDIUM; PATIENT COMPLIANCE; PRESCRIPTIONS, DRUG; PYRIDONES; SIDEROPHORES; THALASSEMIA; TRIAZOLES;

EID: 41149127679     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2008.tb01523.x     Document Type: Editorial

References (13)

1. Modell B, Letsky EA, Flynn DM, et al. Survival and desferrioxamine in thalassaemia major. Br Med J (Clin Res Ed) 1982; 284: 1081-1084.
2. Modell B, Khan M, Darlison M. Survival in beta-thalassemia major in the UK: data from the UK Thalassemia Register. Lancet 2000; 355: 2051-2052.
3. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004; 89: 1187-1193.
4. Berdoukas V, Dakin C, Freeman A, et al. Lack of correlation between iron overload cardiac dysfunction and needle liver biopsy iron concentration. Haematologica 2005; 90: 685-686.
5. Aessopos A, Fragodimitri C, Karabatsos F, et al. Cardiac magnetic resonance imaging R2* assessments and analysis of historical parameters in patients with transfusion-dependent thalassemia. Haematologica 2007; 92: 131-132.
6. Tanner MA, Galanello R, Dessi C, et al. Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. J Cardiovasc Magn Reson 2006; 8: 543-547.
7. Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006; 107: 3738-3744.
8. Farmaki K, Angelopoulos N, Anagnostopoulos G, et al. Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major. Br J Haematol 2006; 134: 438-444.
9. Tsironi M, Deftereos S, Andriopoulos P, et al. Reversal of heart failure in thalassemia major by combined chelation therapy: a case report. Eur J Haematol 2005; 74: 84-85.
10. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006; 107: 3733-3737.
11. Telfer P, Coen PG, Christou S, et al. Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004. Haematologica 2006; 91: 1187-1192.
12. Kidson-Gerber GL, Francis S, Lindeman R. Management and clinical outcomes of transfusion-dependent thalassaemia major in an Australian tertiary referral clinic. Med J Aust 2008; 188: 72-75.
13. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006; 107: 3455-3462.